GlassScriptPhysician profile
Charles C Ho
NPI 1780685834
$8,471.65
in general payments reported to CMS, 2019-2025
22 companies · $793 in 2025
The $793 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,581 · 2020: $311 · 2021: $810 · 2022: $1,752 · 2023: $1,036 · 2024: $1,187 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,017.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $2,358.39 | 2019-2025 | Tecnis Iol, Tecnis Simplicity |
| Sun Pharmaceutical Industries INC. | $1,804.73 | 2019-2025 | Cequa |
| Alcon Vision LLC | $1,446.80 | 2019-2025 | Clareon, Argos, Rocklatan |
| Glaukos Corporation | $533.81 | 2019-2025 | |
| Oyster Point Pharma, INC. | $351.68 | 2022-2025 | Tyrvaya |
| Harrow Eye, LLC | $305.48 | 2024 | Vevye |
| Allergan, INC. | $216.97 | 2019-2022 | |
| Abbvie INC. | $196.15 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $163.73 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $148.43 | 2022-2025 | Miebo, Xiidra, Scoutpro Osmolarity System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $144.66 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $134.83 | 2021 | |
| Kala Pharmaceuticals, INC. | $131.28 | 2019-2022 | |
| Amgen INC. | $118.86 | 2024-2025 | Tepezza |
| Spark Therapeutics, INC. | $95.73 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $92.74 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $66.59 | 2019 | |
| Aerie Pharmaceuticals, INC. | $44.18 | 2021 | |
| Dompe US, INC. | $37.53 | 2024-2025 | Oxervate |
| Shire North American Group INC | $36.90 | 2019 | |
| Akorn, INC. | $23.58 | 2019 | |
| Horizon Therapeutics Plc | $18.60 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.